Notably, activation of the PI3K/AKT/mTOR pathway in NSCLC results in a more aggressive disease that correlates with poor prognosis for patients and causes resistance to agents that target upstream receptor tyrosine kinases [37, 38]. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.